angiotensin ii has been researched along with mk 2206 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, X; Li, X; Tian, J; Zhou, Z | 1 |
| Miao, FA; Xu, JG; Zhang, GH; Zhang, Y | 1 |
2 other study(ies) available for angiotensin ii and mk 2206
| Article | Year |
|---|---|
Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Angiotensin II; Animals; Cell Line; Diabetes Mellitus, Experimental; Endostatins; Heterocyclic Compounds, 3-Ring; Male; Membrane Proteins; Mice; Phosphorylation; Podocytes; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Streptozocin; Vascular Endothelial Growth Factor A | 2014 |
Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Heterocyclic Compounds, 3-Ring; Humans; Losartan; Lymph Nodes; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Angiotensin, Type 1; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays | 2020 |